


ALB-127158(a)

Cat. No.:	HY-111398		
CAS No.:	1173154-32-9		
Molecular Formula:	C ₂₃ H ₂₁ FN ₄ O ₂		
Molecular Weight:	404.44		
Target:	MCHR1 (GPR24)		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

Ethanol : 2 mg/mL (4.95 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
	Concentration				
	1 mM		2.4726 mL	12.3628 mL	24.7255 mL
	5 mM		0.4945 mL	2.4726 mL	4.9451 mL
	10 mM		0.2473 mL	1.2363 mL	2.4726 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	ALB-127158(a) is a potent and selective melanin concentrating hormone 1 (MCH ₁) receptor antagonist.
IC ₅₀ & Target	MCH ₁ receptor ^[1]
In Vitro	ALB-127158(a) has high affinity for the MCH ₁ receptor (7 nM) with good selectivity over a range of other G-protein coupled receptors (GPCRs), ion channels and transporters, including the MCH ₂ receptor. In vitro functional assays confirmed that ALB-127158(a) is a potent and selective MCH ₁ receptor antagonist ^[1] .
In Vivo	In a mouse diet induced obesity (DIO) model, ALB-127158(a) produces a significant sustained decrease in body weight and food intake in the range of 5-15 mg/kg bid. The weight reduction is predominantly due to a decrease in fat content. In high fat diet (HFD) rats, ALB-127158(a) produces significant weight loss and food reduction at doses as low as 1.25 mg/kg po. Doses > 1.25 mg/kg po produces weight loss > 6%, maximal weight loss of about 10% in rats is observed at 10 mg/kg. Following single and multiple oral administration of ALB-127158(a), ALB-127158(a) is rapidly absorbed (median t _{max} attains between 1 and 3 h post dose in lean and overweight/obese subjects) with a trend to

decrease over dose suggesting a slower absorption rate of ALB-127158(a) at lower doses. After single doses, ALB-127158(a) has a mean half-life ($t_{1/2}$) of 18 to 21 h. Slightly longer mean $t_{1/2}$ estimates of approximately 26 h are obtained following multiple dosing in overweight/obese subjects; steady-state plasma ALB-127158(a) is attained within 6 to 8 days of dosing^[1].

REFERENCES

[1]. Moore NA, et al. From preclinical to clinical development: the example of a novel treatment for obesity. *Neurobiol Dis.* 2014 Jan;61:47-54.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA